Your session is about to expire
← Back to Search
Serplulimab + Chemotherapy for Small Cell Lung Cancer
Study Summary
The trial is studying whether Serplulimab — a drug approved for small cell lung cancer treatment in China — is safer and more effective than the current standard of care (Atezolizumab).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Serplulimab Efficacy
Patients demonstrated better survival rates when receiving Serplulimab than chemotherapy alone.
Serplulimab + Chemo
Chemo alone
Overall Survival %
Duration of survival, month
Serplulimab Efficacy
Serplulimab led to >5x improvement in two year overall survival.
2-Year Overall Survival %
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Travel, including flights, are covered
Your expenses for travel tickets for this trial will be reimbursed.
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Media Library
- I have not received any treatment for my small cell lung cancer.I have had another type of cancer besides small cell lung cancer in the last 5 years.I have no active cancer and no history of cancer in the last 5 years, except for certain skin, bladder, prostate, cervical, or breast cancers that were treated and cured.I have been diagnosed with Non-Small Cell Lung Cancer.I can move around freely despite my symptoms.My small cell lung cancer has spread to other parts of my body.I have been newly diagnosed with early-stage small cell lung cancer.I have tested positive for HIV, Hepatitis B, or Hepatitis C.I have undergone treatment for small cell lung cancer.Answer yes if you do not have HIV, Hepatitis B or Hepatitis C
- Group 1: Serplulimab + carboplatin/cisplatin-etoposide + radiotherapy
- Group 2: placebo + carboplatin/cisplatin-etoposide + radiotherapy
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Verified Trial Data - This sponsor has confirmed the contact details & information for their site to make enrollment simpler.
- Screening: It may take up to 28 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 12 Months
- Follow Ups: You may be asked to continue sharing information regarding the trial for 60 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA cleared HLX10 + carboplatin/cisplatin-etoposide + radiotherapy for patient use?
"This proposed treatment, HLX10 + carboplatin/cisplatin-etoposide + radiotherapy, has received a score of 3 for safety. This is due to the fact that this is a Phase 3 trial, which means that efficacy has been supported by some data and safety has been corroborated by multiple rounds of testing."
Are investigators still signing up people for this experiment?
"This study appears to be actively recruiting patients according to the clinicaltrials.gov website. The trial was first posted on May 17th, 2022 and was most recently updated on October 28th, 2022."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How old are they?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Research Site - Redlands: < 24 hours
- The Center for Cancer and Blood Disorders: < 24 hours
- Research Site - Chicago: < 24 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger